Cannabis in Israel

In 2023, growth in the number of medical cannabis patients slowed significantly in Israel. In the first half of the year the number of medical patients grew by only 1,500; meanwhile, in 2021 monthly growth averaged 2,400, while in 2022 it was 1,220. This slow growth has led to challenges for Israeli cannabis companies, with many becoming unprofitable, some going bankrupt, and others resizing their activities in the market, including outsourcing their operations and closing their facilities.

The Cannabis in Israel market report offers a comprehensive guide to the size and shape of this emerging market opportunity at a national level. It provides the latest retail sales data (historic date range), allowing you to identify the key cannabinoid categories driving growth. It outlines the regulatory, cultural and commercial context and offers strategic analysis of key factors influencing the market – legislative developments both current and future, economic/lifestyle influences, illicit consumption, product innovation, distribution and pricing trends. Forecasts to 2028 illustrate how the market is set to expand and change.

Product coverage: Adult-Use Cannabis, CBD & Other Non-Intoxicating Cannabinoids, Medical Cannabis.

Data coverage: Market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?

• Get a detailed picture of the Cannabis market;
• Pinpoint growth sectors and identify factors driving change;
• Understand the competitive environment, the market’s major players and leading brands;
• Use five-year forecasts to assess how the market is predicted to develop.